This insight highlights LPCAT2's potential as a novel therapeutic target and underscores the importance of addressing genetic variations to enable prognosis and personalized treatment strategies, ultimately broadening the scope of care for diverse populations affected by AD. This evidence concerns the gene LPCAT2 and Alzheimer disease.